Haight, P., Sanchez, M., Thomas, S., Smitherman, C., Cosgrove, C., Bae-Jump, V., … Backes, F. (2024). Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer. In GYNECOLOGIC ONCOLOGY (Vol. 190, pp. S78–S79).

Haight, Paulina, Marilyn Sanchez, Samantha Thomas, Carson Smitherman, Casey Cosgrove, Victoria Bae-Jump, Sarah Crafton, et al. “Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer.” In GYNECOLOGIC ONCOLOGY, 190:S78–79, 2024.

Haight P, Sanchez M, Thomas S, Smitherman C, Cosgrove C, Bae-Jump V, et al. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer. In: GYNECOLOGIC ONCOLOGY. 2024. p. S78–9.

Haight, Paulina, et al. “Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer.” GYNECOLOGIC ONCOLOGY, vol. 190, 2024, pp. S78–79.

Haight P, Sanchez M, Thomas S, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen M, Pothuri B, Powell K, Thaker P, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny G, Wright J, Secord AA, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer. GYNECOLOGIC ONCOLOGY. 2024. p. S78–S79.